Effective generation of tumor-targeted T cells derived from pluripotent stem cells
US10370452B2 · kind B2 · utility
14Cited by
3References
96Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2015 |
| Grant date | Aug 6, 2019 |
| Priority date | — |
| Expiry date | Oct 10, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.